Home > Healthcare > Pharmaceuticals > Finished Drug Form > Preterm Birth Prevention and Management Market

Preterm Birth Prevention and Management Market Share

Report ID: GMI12732
Published Date: Dec 2024
Report Format: PDF

Download Free Sample

Preterm Birth Prevention and Management Market Share

The market is characterized by a mix of pharmaceutical companies, medical device manufacturers, and healthcare providers offering a range of products and services. Key players focus on developing advanced treatments, such as progesterone therapies, tocolytics, and diagnostic tools for early detection. Additionally, hospitals and specialized maternal care centers play a crucial role in providing management solutions. The market is highly competitive, with companies investing in R&D and strategic partnerships to improve preterm birth prevention strategies and enhance maternal and neonatal health outcomes.

Preterm Birth Prevention and Management Market Companies

Prominent players operating in the preterm birth prevention and management industry include:

AbbVie
AMAG Pharmaceuticals
Ferring Pharmaceutical
Merck
Obseva
Pfizer
Takeda Pharmaceutical

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global preterm birth prevention and management industry was valued at USD 1.8 billion in 2024 and is projected to grow at a CAGR of 7.7% from 2025 to 2034, driven by increasing preterm birth rates and advancements in medical technology.

The progesterone therapy segment is expected to grow at a CAGR of 8%, reaching over USD 1.5 billion by 2034, as it significantly reduces the risk of preterm birth in high-risk women.

The U.S. market was valued at USD 671.6 million in 2024 and is anticipated to grow at a CAGR of 7.2% from 2025 to 2034, supported by the country’s relatively high preterm birth rate of approximately 10%.

Key players in the market include AbbVie, AMAG Pharmaceuticals, Ferring Pharmaceutical, Merck, Obseva, Pfizer, and Takeda Pharmaceutical.